Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
Albisinni S, Artigas C, Aoun F, Biaou I, Grosman J, Gil T, Hawaux E, Limani K, Otte FX, Peltier A, Sideris S, Sirtaine N, Flamen P, van Velthoven R. Albisinni S, et al. Among authors: otte fx. BJU Int. 2017 Aug;120(2):197-203. doi: 10.1111/bju.13739. Epub 2017 Jan 4. BJU Int. 2017. PMID: 27981732
Oligometastatic Disease Detection with 68Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact.
Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, Gil T, Peltier A, Van Gestel D, Flamen P. Artigas C, et al. Among authors: otte fx. Cancers (Basel). 2021 Oct 4;13(19):4982. doi: 10.3390/cancers13194982. Cancers (Basel). 2021. PMID: 34638466 Free PMC article.
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P, Strijbos M, den Mooter TV, Liefhooghe N, Bruwaene SV, Uvin P, Ghysel C, Ost D, Schatteman P, Bral S, Engels B, den Begin RV, Otte FX, Roumeguere T, Palumbo S, Neybuch Y, Fonteyne V, Ost P, Dirix L. Dirix P, et al. Among authors: otte fx. Future Oncol. 2020 Jun;16(16):1083-1189. doi: 10.2217/fon-2020-0056. Epub 2020 May 1. Future Oncol. 2020. PMID: 32356465
Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancer.
Sousa F, Jourani Y, Van den Begin R, Otte FX, Ridai S, Desle M, Ferreira A, Ahmimed R, van Klink-de Goeij MCM, Van Gestel D. Sousa F, et al. Among authors: otte fx. Tech Innov Patient Support Radiat Oncol. 2021 Apr 20;18:22-28. doi: 10.1016/j.tipsro.2021.03.003. eCollection 2021 Jun. Tech Innov Patient Support Radiat Oncol. 2021. PMID: 33997323 Free PMC article.
Lymphocyte-sparing pelvic radiotherapy for prostate cancer: An in-silico study.
Baré M, Poeta S, Fernandes P, Jourani Y, Otte FX, Van Brussel S, Van Gestel D, Van den Begin R. Baré M, et al. Among authors: otte fx. Phys Imaging Radiat Oncol. 2022 Jul 30;23:127-133. doi: 10.1016/j.phro.2022.07.006. eCollection 2022 Jul. Phys Imaging Radiat Oncol. 2022. PMID: 35941862 Free PMC article.
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Achard V, et al. Among authors: otte fx. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. Radiother Oncol. 2022. PMID: 35476942 Free article. Clinical Trial.
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Everaerts W, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Scorsetti M, Zapatero A, Villafranca Iturre AE, Eito C, Couñago F, Muto P, Van De Voorde L, Mach N, Bultijnck R, Fonteyne V, Moon D, Thon K, Mercier C, Achard V, Stellamans K, Goetghebeur E, Reynders D, Zilli T. Ost P, et al. Among authors: otte fx. Eur Urol Oncol. 2024 Jun;7(3):462-468. doi: 10.1016/j.euo.2023.09.007. Epub 2023 Oct 9. Eur Urol Oncol. 2024. PMID: 37821242 Clinical Trial.
Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.
Artigas C, Alexiou J, Garcia C, Wimana Z, Otte FX, Gil T, Van Velthoven R, Flamen P. Artigas C, et al. Among authors: otte fx. Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):195-196. doi: 10.1007/s00259-015-3236-x. Epub 2015 Oct 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26502983 No abstract available.